Glynn RJ - Search Results

1

Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, Goldhaber SZ, King CR, Giri T, McLeod HL, Glynn RJ, Gage BF. Ferder NS, et al. Among authors: glynn rj. J Thromb Haemost. 2010 Jan;8(1):95-100. doi: 10.1111/j.1538-7836.2009.03677.x. Epub 2009 Oct 30. J Thromb Haemost. 2010. PMID: 19874474 Free PMC article. Clinical Trial.

2

Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Ridker PM, et al. Among authors: glynn rj. Ann Intern Med. 1997 Apr 1;126(7):528-31. doi: 10.7326/0003-4819-126-7-199704010-00005. Ann Intern Med. 1997. PMID: 9092318

3

Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.

Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace FJ Jr, Rapaport E, Ridker PM, Rouleau JL, Solomon SD, Hennekens CH. Pfeffer MA, et al. Among authors: glynn rj. Circulation. 1997 Jun 17;95(12):2643-51. doi: 10.1161/01.cir.95.12.2643. Circulation. 1997. PMID: 9193433 Clinical Trial.

4

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

Ridker PM, Glynn RJ, Hennekens CH. Ridker PM, et al. Among authors: glynn rj. Circulation. 1998 May 26;97(20):2007-11. doi: 10.1161/01.cir.97.20.2007. Circulation. 1998. PMID: 9610529 Clinical Trial.

5

High levels of plasma C-reactive protein and future risk of age-related cataract.

Schaumberg DA, Ridker PM, Glynn RJ, Christen WG, Dana MR, Hennekens CH. Schaumberg DA, et al. Among authors: glynn rj. Ann Epidemiol. 1999 Apr;9(3):166-71. doi: 10.1016/s1047-2797(98)00049-0. Ann Epidemiol. 1999. PMID: 10192648

6

Alcohol consumption and plasma concentration of C-reactive protein.

Albert MA, Glynn RJ, Ridker PM. Albert MA, et al. Among authors: glynn rj. Circulation. 2003 Jan 28;107(3):443-7. doi: 10.1161/01.cir.0000045669.16499.ec. Circulation. 2003. PMID: 12551869 Clinical Trial.

7

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Ridker PM, et al. Among authors: glynn rj. N Engl J Med. 2003 Apr 10;348(15):1425-34. doi: 10.1056/NEJMoa035029. Epub 2003 Feb 24. N Engl J Med. 2003. PMID: 12601075 Free article. Clinical Trial.

8

Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score.

Albert MA, Glynn RJ, Ridker PM. Albert MA, et al. Among authors: glynn rj. Circulation. 2003 Jul 15;108(2):161-5. doi: 10.1161/01.CIR.0000080289.72166.CF. Epub 2003 Jun 30. Circulation. 2003. PMID: 12835213 Free article.

9

Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism.

Ridker PM, Goldhaber SZ, Glynn RJ. Ridker PM, et al. Among authors: glynn rj. N Engl J Med. 2003 Nov 27;349(22):2164-7; author reply 2164-7. N Engl J Med. 2003. PMID: 14658125 No abstract available.

10

Effect of physical activity on serum C-reactive protein.

Albert MA, Glynn RJ, Ridker PM. Albert MA, et al. Among authors: glynn rj. Am J Cardiol. 2004 Jan 15;93(2):221-5. doi: 10.1016/j.amjcard.2003.09.046. Am J Cardiol. 2004. PMID: 14715354 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

705 results

Search Page

Filters